Oxidative stress contributes to the pathophysiology of interstitial lung diseases, such as cryptogenic fibrosing alveolitis (CFA), fibrosing alveolitis associated with systemic sclerosis (FASSc) and sarcoidosis. F2-isoprostanes are a series of prostaglandin (PG) F 2 -like compounds produced in vivo independent of cyclooxygenase, as products of the radical-catalyzed lipid peroxidation. Measurement of the concentrations of F2-isoprostanes has proved to be valuable in assessing oxidative stress in vivo . The aim of this study was to measure 8-epi-PGF 2 ␣ concentrations, one of the most abundant F2-isoprostane in humans, in bronchoalveolar lavage (BAL) in normal subjects and to compare them to those observed in patients with CFA (n ϭ 9), FASSc (n ϭ 8) and sarcoidosis (n ϭ 10). 8-epi-PGF 2 ␣ was detectable in BAL fluid in normal subjects (9.6 Ϯ 0.8 pg/ml) and its concentrations were increased ap- 
Interstitial lung diseases, such as cryptogenic fibrosing alveolitis (CFA) and fibrosing alveolitis associated with systemic sclerosis (FASSc), are characterized by enhanced oxidative stress (1) (2) (3) (4) (5) . An imbalance between oxidants and antioxidants may also be important in the pathogenesis of sarcoidosis (6, 7) , in which interstitial fibrosis is also present in the more advanced stages of the disease. Alveolar macrophages isolated from patients with both CFA and sarcoidosis produce increased amounts of superoxide anions when cultured in vitro (8) (9) (10) . Moreover, indicators of free radical activity are increased in the patients with interstitial lung diseases in both serum (11) and bronchoalveolar lavage (BAL) fluid (12) . Isoeicosanoids or isoprostanes are free radical catalyzed products of arachidonic acid which are formed in situ in the cell membrane phospholipids, from which they are cleaved, presumably by phospholipase (s) A 2 (13) (14) (15) . Measurements of isoprostanes in plasma, urine, or other biological fluids may therefore provide a quantitative index of oxidant stress in vivo (16) .
8-epi-prostaglandin F2 alpha (8-epi-PGF 2 ␣ ), a member of the F2-isoprostane class, has been detected in plasma and urine in humans (15, 17) and 8-epi-PGF 2 ␣ concentrations are increased in smokers (18) , in hepatorenal syndrome and acute paracetamol intoxication (19) when the production of reactive oxygen species (ROS) is increased. Recently, Stein and coworkers reported an increase in urinary 8-epi-PGF 2 ␣ concentrations in patients with scleroderma (20) . The aim of this study was to investigate whether 8-epi-PGF 2 ␣ could be detectable in BAL fluid in patients with interstitial lung diseases and to compare its concentrations in those patients and in healthy subjects.
METHODS

Patients
Nine patients with CFA (mean age Ϯ SEM, 56 Ϯ 2 yr, 5 male) were included in the study on the basis of clinical diagnostic criteria for CFA (21) consisting of bilateral basal or widespread crackles on auscultation of the chest, a restrictive defect or reduction in transfer factor of the lung for carbon monoxide (TL CO ) on pulmonary function testing, computed tomography abnormalities compatible with a diagnosis of fibrosing alveolitis (22, 23) , and the absence of exposure to a recognized fibrogenic agent. In one of the patients, the diagnosis was confirmed histologically by open lung biopsy. Eight patients with FASSc (53.4 Ϯ 18.9 yr, 3 male) met American Rheumatism Associa-tion preliminary criteria for the diagnosis of scleroderma (24) , and also fulfilled the criteria for fibrosing alveolitis (21) . In two of them the diagnosis was histologically confirmed by transbronchial biopsy. Exclusion criteria were: (a) rheumatological overlap syndrome, (b) pulmonary hypertension, (c) other respiratory disease, (d) respiratory tract infection. The BAL was performed in the middle lobe of all patients. All patients with CFA and FASSc had widespread involvement of the lungs on high-resolution computed tomography (HRCT) scan (one in the CFA group and one in the FASSc group had a predominant upper lobe reticular shadowing; one patient in the FASSc group had a lower lobe reticular pattern). Ten patients with sarcoidosis were included in the study and the diagnosis was made using conventional criteria, including biopsy (transbronchial in 5; Kveim test in 4; lymphonodes in 1) (25) . The radiographic stage of sarcoidosis was grade I (bronchial-hilar lymphonode involvement) in two patients, grade II (bronchial-hilar lymphonode involvement and parenchymal disease) in six patients, and grade III (parenchymal disease alone) in two patients.
None of the patients was a current smoker and smoking history was similar in the three disease groups (CFA, FASSc, and sarcoidosis) ( Table 1 ). Two patients with CFA, two patients with FASSc, and three patients with sarcoidosis were on steroid treatment (prednisolone 30 mg/d). One patient with FASSc was treated with penicillamine. In all patients there were no echocardiographic signs of pulmonary hypertension; echocardiography was performed no later than 2 mo before entering the study.
Pulmonary Function Testing
Pulmonary function tests were performed within 2 wk of the measurement of exhaled nitric oxide (NO). Forced expiratory flow volume curves were obtained using a spirometer (Erich Jaeger, Market Hardborough, UK). Measures of diffusing capacity (TL CO ) were performed by single-breath technique (Transfer Factor Erich Jaeger, Market Hardborough, UK). Arterialized capillary blood gases were analyzed using a Corning 248 blood gas analyzer (Ciba Corning, Halstead, UK).
Thin-Section Computed Tomography
CT sections were acquired using a high resolution fast scanner (Imatron Inc., San Francisco, CA). Interspaced 3-mm sections were obtained from the lung apices to the lung bases, with the patients in the supine position. Scans were analyzed by an experienced thoracic radiologist and an assessment made of presence or absence of a pattern consistent with fibrosing alveolitis.
Bronchoscopy and BAL
Bronchoscopy with BAL was performed with the informed consent of the patient on the same day and after exhaled NO measurement. BAL cell counts were assessed as previously reported (26) . BAL was considered to be active when any one of the following criteria was met: ( 1 ) lymphocytes Ͼ 14%, ( 2 ) neutrophils Ͼ 4%, ( 3 ) eosinophils Ͼ 3%, each of which indicates abnormal inflammatory cell numbers (27) .
Measurement of Immunoreactive 8-epi-PGF 2 ␣ Concentrations
8-epi-PGF 2 ␣ concentrations in BAL were measured by a specific enzyme immunoassay (EIA) kit (Cayman Chemical, Ann Arbor, MI). Samples were centrifuged and the supernatants were collected and stored at Ϫ 70 Њ C until assayed. The assay has been validated to obtain a high correlation (0.95) between added known amounts of 8-epi-PGF 2 ␣ and the concentration measured by EIA and has been directly validated by gas chromatography/mass spectrometry. The antiserum used in this assay has a 100% cross-reactivity with 8-epi-PGF 2 ␣ , 0.2% each with PGF 2 ␣ , PGF 3 ␣ , PGE 1 and PGE 2 , 0.1% each with 6-keto-PGF 1 ␣ . The detection limit of the assay is 4 pg/ml. This kit has been used to measure 8-epi-PGF 2 ␣ concentrations in rat human urine, plasma, and BAL (28).
Exhaled NO Measurement
Exhaled NO was measured using a modified chemiluminescence analyzer (model LR2000; Logan Research, Rochester, UK), sensitive to NO from 1 to 5,000 ppb, (by volume), and with a resolution of 0.3 ppb, which was designed for on-line recording of exhaled NO concentration, as previously described (29) . The analyzer was calibrated using certified NO mixtures (90 ppb and 436 ppb) in nitrogen (BOC Special Gases, Guilford, UK). Measurements of exhaled NO were made by slow exhalation (5 to 6 L/min) from total lung capacity (TLC) for 20 to 30 s against a resistance (3 Ϯ 0.4 mm Hg).
Statistical Analysis
For parametric data Student's unpaired t test was used to compare groups, for nonparametric data Mann-Whitney U tests (BAL analysis) were used. Linear regression analysis was used to assess the relationship between 8-epi-PGF 2 ␣ and BAL cell counts and between exhaled NO and 8-epi-PGF 2 ␣ . All data were expressed as means Ϯ standard error of mean. Significance was defined as a p value of Ͻ 0.05.
RESULTS
Clinical data and BAL findings of healthy subjects and patients with CFA, FASSc, and sarcoidosis are summarized in Tables 1 and 2 , respectively. 8-epi-PGF 2 ␣ concentrations were detectable (9.6 Ϯ 0.8 pg/ml) in BAL of normal subjects and were increased approximately 5-fold in patients with CFA (47.4 Ϯ 7.0 pg/ml, p Ͻ 0.001) and FASSc (43.2 Ϯ 3.3 pg/ml, p Ͻ 0.001) (Figure 1 ). Compared with normal subjects, 8-epi-PGF 2 ␣ levels were also increased in patients with sarcoidosis, although to a lesser extent than in patients with CFA and FASSc (12.0 Ϯ 0.7 pg/ml, p Ͻ 0.005) (Figure 1 ). In patients with sarcoidosis, The highest level of free radical activity as reflected by 8-epi-PGF 2␣ concentrations in BAL was found in the patients with CFA and FASSc. For this reason, we measured exhaled NO, another potential biomarker of oxidative stress, in the same study groups. Compared with normal subjects (6.9 Ϯ 0.50 ppb, p Ͻ 0.05), exhaled NO was increased in both CFA (11.8 Ϯ 0.7 ppb, p Ͻ 0.05) and FASSc patients (10.7 Ϯ 0.50 ppb, p Ͻ 0.05). 8-epi-PGF 2␣ correlated with NO levels in patients with CFA (r ϭ 0.78, p Ͻ 0.05) (Figure 2 ), but no correlation was observed in the patients with FASSc (Figure 3 ).
DISCUSSION
8-epi-PGF 2␣ is the best characterized compound belonging to the F2-isoprostanes, a group of PGF 2␣ isomers formed by free radical peroxidation of arachidonic acid, independent of the action of cyclooxygenase (30) . Urinary excretion of 8-epi-PGF 2␣ is enhanced in clinical conditions associated with oxidative stress in vivo (31) , including scleroderma (20) . For this reason, 8-epi-PGF 2␣ has been considered as an ideal marker for the pathophysiology of oxidative injury. Several studies have shown that 8-epi-PGF 2␣ may also be produced by cyclooxygenase-1 and -2 activity in several cells and tissues (32) (33) (34) . However, despite its possible enzymatic synthesis, this isoprostane is still considered a reliable biomarker of lipid peroxidation due to ROS (35) .
The results of this study show that 8-epi-PGF 2␣ is detectable in BAL fluid of normal subjects and the levels are comparable with those reported in a previous study in which the same analytical technique was used (27) .
Sarcoidosis and fibrosing interstitial lung diseases have different severity and prognosis. 8-epi-PGF 2␣ concentrations were increased in all patients, but they were almost 4-fold as high in patients with CFA and FASSc as in patients with sarcoidosis, suggesting a higher level of oxidant stress in the former diseases and consistent with the knowledge that there is greater lung injury in fibrosing alveolitis than in sarcoidosis. Consistent with our findings, overproduction of a tetranor-dicarboxylic acid metabolite of F2-isoprostanes in urine has recently been reported in patients with scleroderma (19) .
In patients with CFA and FASSc, a pathogenetic role for ROS was also supported by increased concentrations of exhaled NO, another potential biomarker of oxidative stress. NO correlated with 8-epi-PGF 2␣ in patients with CFA, but not in patients with FASSc. Considering that 8-epi-PGF 2␣ is mainly derived from lipid peroxidation of arachidonic acid in phospholipids of plasma membranes, whereas NO is primarily produced during oxidative bursts, it is possible that different mechanisms of oxidative stress might contribute in CFA and FASSc. This may be of relevance clinically, in that FASSc carries a better prognosis than CFA even when matched for clinical severity, suggesting that these two types of fibrosing alveolitis have different underlying mechanisms.
The lack of correlation between 8-epi-PGF 2␣ and lung function tests could be due to different pathophysiological relevance of these biomarkers. Lung function test impairment is the result of previous lung damage, while the isoprostane levels are likely to reflect the current pathological situation. 8-epi-PGF 2␣ concentrations in BAL might, therefore, be useful as biomarkers of subsequent changes, although further studies are needed for a complete characterization of the role of 8-epi-PGF 2␣ as a biomarker of disease progression in patients with interstitial lung diseases.
In conclusion, we have shown that the level of oxidative stress is enhanced in patients with fibrosing alveolitis and, to a lesser extent, with sarcoidosis, as reflected by increased concentrations of 8-epi-PGF 2␣ in BAL fluid. This isoprostane may, therefore, be useful as a quantitative index in vivo of an important aspect of the pathophysiology of these diseases. Further studies are needed to investigate whether this isoprostane is measurable in other biological fluid that can be sampled by noninvasive procedures, such as breath condensate, and to explore whether antioxidant therapy may influence its concentrations in BAL. Finally, further research is required to identify the cellular sources of 8-epi-PGF 2␣ and to quantify its possible enzymatic synthesis.
